Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J, Smith FO.

Blood. 2011 Dec 22;118(26):6752-9; quiz 6996. doi: 10.1182/blood-2011-04-350017.

3.

[GATA1-mutation associated leukemia in children with trisomy 21 mosaic].

Reinhardt D, Reinhardt K, Neuhoff C, Sander A, Klusmann JH, Pekrun A, Sauerbrey A, von Stackelberg A, Rössig C, Creutzig U, Kolenova A.

Klin Padiatr. 2012 Apr;224(3):153-5. doi: 10.1055/s-0032-1308988. German.

PMID:
22513796
4.

Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.

Xu G, Kato K, Toki T, Takahashi Y, Terui K, Ito E.

J Pediatr Hematol Oncol. 2006 Oct;28(10):696-8.

PMID:
17023834
5.

Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.

Sorrell AD, Alonzo TA, Hilden JM, Gerbing RB, Loew TW, Hathaway L, Barnard D, Taub JW, Ravindranath Y, Smith FO, Arceci RJ, Woods WG, Gamis AS.

Cancer. 2012 Oct 1;118(19):4806-14. doi: 10.1002/cncr.27484.

6.

Acute megakaryoblastic leukemia following transient myeloproliferative disorder in a patient without Down syndrome.

Brissette MD, Duval-Arnould BJ, Gordon BG, Cotelingam JD.

Am J Hematol. 1994 Dec;47(4):316-9.

PMID:
7977305
7.

Transient myeloproliferative disorder and GATA1 mutation in neonates with and without Down syndrome.

Tsai MH, Hou JW, Yang CP, Yang PH, Chu SM, Hsu JF, Chiang MC, Huang HR.

Indian J Pediatr. 2011 Jul;78(7):826-32. doi: 10.1007/s12098-010-0312-x.

PMID:
21287369
8.

Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome.

Boztug H, Schumich A, Pötschger U, Mühlegger N, Kolenova A, Reinhardt K, Dworzak M.

Cytometry B Clin Cytom. 2013 Nov-Dec;84(6):370-8. doi: 10.1002/cyto.b.21082.

9.
10.

Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.

Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD.

Blood Cells Mol Dis. 2003 Nov-Dec;31(3):351-6.

PMID:
14636651
11.

Long-term outcome for Down syndrome patients with hematopoietic disorders.

Li MJ, Lee NC, Yang YL, Yen HJ, Chang HH, Chien YH, Lu MY, Jou ST, Lin KH, Hwu WL, Lin DT.

J Formos Med Assoc. 2016 Feb;115(2):94-9. doi: 10.1016/j.jfma.2015.01.009.

12.

Erythroblastic and/or megakaryoblastic leukemia in Down syndrome: treatment with low-dose arabinosyl cytosine.

Tchernia G, Lejeune F, Boccara JF, Denavit MF, Dommergues JP, Bernaudin F.

J Pediatr Hematol Oncol. 1996 Feb;18(1):59-62.

PMID:
8556372
13.

A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481.

Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, Ravindranath Y, Dahl G, Weinstein HJ; Children's Oncology Group (COG)..

Blood. 2006 Jun 15;107(12):4606-13.

14.

Megakaryoblastic disorders in children.

Lorsbach RB.

Am J Clin Pathol. 2004 Dec;122 Suppl:S33-46. Review.

PMID:
15690641
15.

Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes.

Apollonsky N, Shende A, Ouansafi I, Brody J, Atlas M, Aygun B.

J Pediatr Hematol Oncol. 2008 Nov;30(11):860-4. doi: 10.1097/MPH.0b013e31818a953e.

PMID:
18989165
16.

Ultrastructural and ultracytochemical differences between transient myeloproliferative disorder and megakaryoblastic leukaemia in Down's syndrome.

Eguchi M, Sakaibara H, Suda J, Ozawa T, Hayashi Y, Sato T, Kojima S, Furukawa T.

Br J Haematol. 1989 Nov;73(3):315-22.

PMID:
2532535
17.

WT1 gene expression in children with Down syndrome and transient myeloproliferative disorder.

Hasle H, Lund B, Nyvold CG, Hokland P, Østergaard M.

Leuk Res. 2006 May;30(5):543-6.

PMID:
16242775
18.

Transient myeloproliferative disorder.

Moiz B, Shafiq M.

Blood. 2012 Dec 6;120(24):4672. No abstract available.

19.

Acute nonlymphocytic leukemia after transient myeloproliferative disorder in a patient with Down syndrome.

Barnett PL, Clark AC, Garson OM.

Med Pediatr Oncol. 1990;18(5):347-53. Review.

PMID:
2142749
20.

Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.

Nikolaev SI, Santoni F, Vannier A, Falconnet E, Giarin E, Basso G, Hoischen A, Veltman JA, Groet J, Nizetic D, Antonarakis SE.

Blood. 2013 Jul 25;122(4):554-61. doi: 10.1182/blood-2013-03-491936.

Items per page

Supplemental Content

Support Center